Boston – September 17, 2026 -- Xylo Bio has dosed the first participants in a Phase 1 clinical trial of XYL-1001, a selective 5-HT2A receptor agonist targeting major depressive disorder (MDD), marking the company's transition to a clinical-stage biotechnology organization.

SHERIDAN, WYOMING -- August 28, 2026 -- SuperX AI Technology Limited (NASDAQ: SUPX) said its subsidiary SuperX Microinference Pte Ltd signed a long-term equipment and services supply agreement with Australian compute provider Ezisight Australia Pty Ltd., trading as Ultimate AI Datacentre, and received an initial purchase order for 128 units of B300 AI server clusters. The Singapore-based company will deliver the servers in the fourth quarter of 2026 for deployment in Ezisight's Australian data centers.